



Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 07, 2023

IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying DetermaIO™ to samples collected from the randomized Phase II AtezoTRIBE clinical trial in metastatic colorectal cancer (mCRC). The results were published in [Clinical Cancer Research](#) and showed the utility of DetermaIO in potentially identifying more responders to ICI therapy than current standard of care biomarkers.

Highlights of the peer-reviewed publication include:

- In the overall population (n=122), DetermaIO positive patients achieved better outcomes in terms of progression-free survival from the addition of atezolizumab among mCRC patients than DetermaIO negative patients, regardless of MMR status.
- A similar trend was observed in the pMMR population (n=110) that does not currently qualify for ICI therapy in mCRC.
- In the pMMR group treated with ICI addition to chemo (N=69), patients that had a very high DetermaIO had a significantly improved progression-free survival (HR=0.19 95%CI: 0.09 - 0.40). Overlap between DetermaIO positive, dMMR, and TMB is limited, demonstrating DetermaIO identifies a unique subset of patients not identified by these biomarkers.

The authors conclude, "Our study demonstrates that the gene expression profiling through the DetermaIO of mCRC would mark a fundamental paradigm shift in the characterization of tumor immune microenvironment of mCRC, by providing the opportunity to identify an immune-enriched tumor microenvironment among pMMR tumors that do not currently qualify for ICI therapy."

About Oncocyte

Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is blood-based monitoring tool for monitoring therapeutic efficacy.

DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation

Investor Contact

Jesse Arno

(949) 409-6770

jarno@oncocyte.com



Source: Oncocyte Corporation

